S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
NASDAQ:FIXX

Homology Medicines (FIXX) Stock Forecast, Price & News

$1.48
-0.07 (-4.52%)
(As of 05/23/2022 04:00 PM ET)
Add
Compare
Today's Range
$1.47
$1.61
50-Day Range
$1.40
$3.49
52-Week Range
$1.33
$8.90
Volume
222,044 shs
Average Volume
539,465 shs
Market Capitalization
$84.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.21
30 days | 90 days | 365 days | Advanced Chart
Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

Homology Medicines logo

About Homology Medicines

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Headlines

Homology Medicines (NASDAQ:FIXX) Price Target Cut to $14.00
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FIXX
Fax
N/A
Employees
224
Year Founded
N/A

Sales & Book Value

Annual Sales
$33.97 million
Book Value
$4.64 per share

Profitability

Net Income
$-95.76 million
Pretax Margin
-18.80%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,933,000
Market Cap
$84.93 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/16/2022
Today
5/23/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.35 out of 5 stars

Medical Sector

260th out of 1,416 stocks

Pharmaceutical Preparations Industry

97th out of 677 stocks

Analyst Opinion: 4.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

Is Homology Medicines a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Homology Medicines stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FIXX, but not buy additional shares or sell existing shares.
View analyst ratings for Homology Medicines
or view top-rated stocks.

Are investors shorting Homology Medicines?

Homology Medicines saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 2,860,000 shares, an increase of 23.8% from the April 15th total of 2,310,000 shares. Based on an average daily volume of 538,500 shares, the short-interest ratio is currently 5.3 days. Approximately 7.1% of the company's stock are sold short.
View Homology Medicines' Short Interest
.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Homology Medicines
.

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) issued its earnings results on Monday, May, 16th. The company reported $1.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $2.10. Homology Medicines had a negative net margin of 47.29% and a negative trailing twelve-month return on equity of 49.48%.
View Homology Medicines' earnings history
.

What price target have analysts set for FIXX?

7 Wall Street analysts have issued 1-year price objectives for Homology Medicines' stock. Their forecasts range from $2.10 to $29.00. On average, they anticipate Homology Medicines' share price to reach $12.90 in the next twelve months. This suggests a possible upside of 771.6% from the stock's current price.
View analysts' price targets for Homology Medicines
or view top-rated stocks among Wall Street analysts.

Who are Homology Medicines' key executives?
Homology Medicines' management team includes the following people:
  • Dr. Arthur O. Tzianabos Ph.D., CEO & Director (Age 59, Pay $912.5k)
  • Dr. Albert Seymour Ph.D., Pres & Chief Scientific Officer (Age 54, Pay $638.7k)
  • Mr. W. Bradford Smith CPA, M.B.A., CFO, Treasurer & Chief Bus. Officer (Age 66, Pay $755.8k) (LinkedIn Profile)
  • Dr. Saswati Chatterjee Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Julie Jordan M.D., Sr. VP and Head of Clinical Devel. & Operations
  • Dr. Paul Alloway J.D., Ph.D., Chief Legal Officer & Sec. (Age 51)
  • Ms. Theresa McNeely, Chief Communications Officer & Patient Advocate (Age 58)
  • Ms. Melissa Gelormini, VP of HR
  • Mr. Michael Blum M.B.A., Chief Commercial Officer (Age 54)
  • Dr. Deborah Kinch Ph.D., Chief Devel. Officer
What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), (CGC) and Inovio Pharmaceuticals (INO).

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.74%), Vanguard Group Inc. (3.11%), Bellevue Group AG (2.87%), State Street Corp (1.73%), Group One Trading L.P. (0.00%) and JPMorgan Chase & Co. (1.28%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, Kush Parmar, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends for Homology Medicines
.

Which institutional investors are selling Homology Medicines stock?

FIXX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Vanguard Group Inc., Bellevue Group AG, JPMorgan Chase & Co., Russell Investments Group Ltd., Acadian Asset Management LLC, Northern Trust Corp, and BNP Paribas Arbitrage SA. Company insiders that have sold Homology Medicines company stock in the last year include Albert Seymour, Arthur Tzianabos, Timothy P Kelly, and W Bradford Smith.
View insider buying and selling activity for Homology Medicines
or view top insider-selling stocks.

Which institutional investors are buying Homology Medicines stock?

FIXX stock was purchased by a variety of institutional investors in the last quarter, including Group One Trading L.P., BlackRock Inc., State Street Corp, Simplex Trading LLC, Renaissance Technologies LLC, Nisa Investment Advisors LLC, Dimensional Fund Advisors LP, and GSA Capital Partners LLP.
View insider buying and selling activity for Homology Medicines
or or view top insider-buying stocks.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $1.48.

How much money does Homology Medicines make?

Homology Medicines has a market capitalization of $84.93 million and generates $33.97 million in revenue each year. The company earns $-95.76 million in net income (profit) each year or ($0.080010) on an earnings per share basis.

How many employees does Homology Medicines have?

Homology Medicines employs 224 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is www.homologymedicines.com.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at (781) 301-7277.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.